Ret-rearranged Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-02-20
Clinical Trial Update: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer [Phase 3]
Phase 3 rollover study of Alectinib in ALK-positive or RET-positive cancers is active but not recruiting.